Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma

Exclusion Criteria

• - Known history of allergy or reaction to any component of the investigational product formulation
• - History of anaphylaxis to any biologic therapy
• - Unexplained diarrhea within 30 days prior to screening or diagnosis of helminth parasitic infestation within 6 months prior to screening
• - Use of immunosuppressive medication within 3 months prior to screening. Chronic oral prednisone or equivalent up to 10 milligram (mg) daily or 20 mg every other day for asthma is allowed
• - Oral corticosteroid burst or short-acting systemic corticosteroid within 30 days prior to screening or during the screening/run-in period
• - Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 30 days prior to the screening or during the screening/run-in period
• - Receipt of immunoglobulin or blood products within 30 days prior to screening
• - Receipt of any marketed or investigational biologic within 4 months or 5 half-lives prior to screening, whichever is longer
• - Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to screening, whichever is longer
• - Previously received MEDI-563
• - Any clinically relevant abnormal findings in physical examination
• - Past history of clinically significant cardiac disease or any electrocardiogram (ECG) abnormality
• - Breastfeeding or lactating women
• - History of alcohol or drug abuse within 12 months prior to screening
• - History of any known primary immunodeficiency disorder
• - Positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enrol
• - A positive human immunodeficiency virus (HIV) test or subject taking antiretroviral medications
• - History of cigarette smoking more than or equal to (>=) 10 pack-years or smoking within 12 months prior to screening.
• - Known exposure to inhaled occupational agents or fumes with an established diagnosis of occupational asthma
• - History of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >=12 months prior to screening or other malignancies treated with apparent success with curative therapy >=5 years prior to screening
• - Stable dose of allergy vaccination regimen for less than 30 days prior to screening
• - Subjects unable to demonstrate acceptable inhaler and peak flow meter techniques.